1 |
Madireddi S, Schabowsky R-H, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventiolnal CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One. 2012. 7: e42459.
DOI
|
2 |
Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 2007. 13: 1440-1449.
DOI
|
3 |
Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor response in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular Immunology. 2001. 210: 56-65.
DOI
|
4 |
Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cellular Immunology. 2009. 256: 39-46.
DOI
|
5 |
Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Research. 2009. 69: 8516-8525.
DOI
|
6 |
Kim HS. Development of genetically modified tumor cell containing c0-stimulatory molecule. Biomedical Science Letters. 2019. 25: 398-406.
DOI
|
7 |
Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4(+) T and natural killer cells. Cancer Research. 2019. 79: 783-794.
DOI
|
8 |
Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. An adenoviral cancer vaccine co-endoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine. 2016. 34: 2147-2156.
DOI
|
9 |
Lee NK, Kim HS. Oncolytic vaccinia virus expressing 4-1BBL inhibits tumor growth by increasing CD8+ T cells in B16F10 tumor model. Biomedical Science Letters. 2012. 18: 210-217.
|
10 |
Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered-4-1BBL fusion protein with "activity on demand". Proceedings of the National Academy of Sciences USA. 2020. 117: 31780-31788.
DOI
|
11 |
Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews. 2009. 229: 192-215.
DOI
|
12 |
Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccine. Expert Review of Vaccines. 2014. 13: 387-398.
DOI
|
13 |
Trub M, Uhlenbrock F, Claus C, Herzig P, Thelen M, Karanikas V, Bacac M, Amann M, Albrecht R, Ferrara-Koller C, Thommen D, Rothschield S, Savic Prince S, Mertz KD, Cathomas G, Rosenberg R, Heinzelmann-Schwarz V, Wiese M, Lardinosis D, Umana P, Klein C, Laubli H, Kashyap AS, Zippelius A. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. Journal for Immunotherpy of Cancer. 2020. 8: e000238.
DOI
|
14 |
Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Molecular Cancer Therapeutics. 2012. 11: 1062-1070.
DOI
|
15 |
Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Yolba KA, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Research. 2007. 67: 10027-10037.
DOI
|
16 |
Wang R, Freywald A, Chen Y, Xu J, Tan X, Xiang J. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming CD44(+)CD62L(high)IL-7R(+) CTLs with up-and downregulation of anti- and pro-apoptosis genes. Cellular & Molecular Immnology. 2015. 12: 456-465.
DOI
|